Oscar Health (OSCR) EBITDA (2020 - 2026)

Oscar Health has reported EBITDA for 7 years, with the latest figure at $60.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 79.6% year-over-year to $60.6 million; the trailing twelve-month figure through Mar 2026 stood at -$165.9 million (down 143.87% YoY), and the FY2025 full-year result was -$396.4 million, down 313.41% from the prior year.
• EBITDA for Q1 2026 stood at $60.6 million, up from -$333.7 million in the prior quarter.
• The five-year high for EBITDA was $297.1 million in Q1 2025, with the low at -$355.5 million in Q4 2023.
• Historically, EBITDA has averaged -$17.3 million across 5 years, with a median of $36.1 million in 2023.
• Annual changes were most pronounced in 2022 — EBITDA slumped 4675.25% — and 2023, when it surged 5073.03%.
• Oscar Health's EBITDA stood at -$222.5 million in 2022, then sank by 59.8% to -$355.5 million in 2023, then surged by 94.58% to -$19.3 million in 2024, then tumbled by 1632.22% to -$333.7 million in 2025, then surged by 118.16% to $60.6 million in 2026.
• The last three EBITDA figures came in at $60.6 million (Q1 2026), -$333.7 million (Q4 2025), and $53.2 million (Q3 2025), per Business Quant data.